Agenus Announces Research Collaboration To Develop Predictive Biomarkers Of Response To Clinical Stage IO Combination, Botensilimab

Author: Benzinga Newsdesk | June 17, 2025 06:31am

• Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients are most likely to benefit from BOT/BAL treatment
• Collaboration builds on landmark 2024 Cancer Discovery study elucidating botensilimab's unique FcγR-mediated immune activation underlying activity in refractory tumors
• Supports AI-enabled biomarker discovery, aligning with the national priorities and the FDA to expand access to personalized cancer treatment

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1). The collaboration harnesses Noetik's proprietary virtual cell foundation models and large-scale, multimodal tumor data to uncover novel insights into the biology of tumor immunology. Together, the teams will deploy Noetik's first-in-class foundation models directly on clinical results with the aim to enrich clinical efficacy.

Posted In: AGEN